High incidence of symptomatic methemoglobinemia (metHb) in Asian patients (pts) treated with 3-Aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP, triapine) and gemcitabine (GEM) in a second-line phase II trial of metastatic non-small cell lung cancer

被引：0
|
作者：
Ma, B.
Tan, E. H.
Mok, T.
Lam, K. C.
Soo, R.
Leong, S. S.
Wang, L. Z.
Mo, F.
Chan, A. T.
Goh, B. C.
机构：
[1] Chinese Univ Hong Kong, Hong Kong, Peoples R China
[2] Natl Canc Ctr, Singapore, Singapore
[3] Natl Univ Singapore Hosp, Singapore, Singapore
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2007年 / 25卷 / 18期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
18207
引用
收藏
页数：2
相关论文
共 50 条
  • [31] Carboplatin (C) and docetaxel (D) in second-line treatment of non-small cell lung cancer (NSCLC) patients (PTS) pretreated with platinum-based combinations (PBC): A phase II trial
    Buffoni, Lucio
    Fea, Elena
    Numico, Gianmauro
    Dongiovanni, Diego
    Barone, Carla
    Schena, Marina
    Colantonio, Ida
    Occelli, Marcella
    Mattiot, Valentina Polla
    Merlano, Marco
    ANNALS OF ONCOLOGY, 2007, 18 : 31 - 31
  • [32] Pemetrexed (P) plus gemcitabine (G) as front-line chemotherapy for patients (Pts) with locally advanced or metastatic non-small cell lung cancer (NSCLC): A phase II clinical trial.
    West, H
    Belt, RJ
    Wakelee, HA
    Bloss, LP
    Taylor, L
    Monberg, MJ
    Ye, Z
    Obasaju, CK
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 649S - 649S
  • [33] Docetaxel/gemcitabine or cisplatin/gemcitabine followed by docetaxel in the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC):: results of a multicentre randomized phase II trial
    Binder, D.
    Schweisfurth, H.
    Grah, C.
    Schaeper, C.
    Temmesfeld-Wollbrueck, B.
    Siebert, G.
    Suttorp, N.
    Beinert, T.
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2007, 60 (01) : 143 - 150
  • [34] Docetaxel/gemcitabine or cisplatin/gemcitabine followed by docetaxel in the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC): results of a multicentre randomized phase II trial
    D. Binder
    H. Schweisfurth
    C. Grah
    C. Schäper
    B. Temmesfeld-Wollbrück
    G. Siebert
    N. Suttorp
    T. Beinert
    Cancer Chemotherapy and Pharmacology, 2007, 60 : 143 - 150
  • [35] Randomized, blinded, placebo-controlled phase II trial of docetaxel and bavituximab as second-line therapy in locally advanced or metastatic non-squamous non-small cell lung cancer
    Shtivelband, Mikhail
    Spigel, David R.
    Gerber, David E.
    Jain, Minish Mahendra
    Ponomarova, Olga V.
    Giorgadze, Davit
    Shan, Joseph
    Menander, Kerstin B.
    Belani, Chandra Prakash
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [36] Docetaxel/gemcitabine vs. cisplatin/gemcitabine followed by docetaxel in the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC):: Results of a randomised phase II trial
    Binder, D
    Schweisfurth, H
    Grah, C
    Schäper, C
    Temmesfeld-Wollbrück, B
    Siebert, G
    Suttorp, N
    Beinert, T
    LUNG CANCER, 2005, 49 : S237 - S237
  • [37] SECOND-LINE ERLOTINIB THERAPY IN ELDERLY PATIENTS WITH ADVANCED NON-SMALL-CELL LUNG CANCER: IFCT-0501 RANDOMISED, PHASE 3 TRIAL
    Quoix, E.
    Westeel, V.
    Oster, J.
    Pichon, E.
    Dauba, J.
    Debieuvre, D.
    Baudrin, L.
    Morin, F.
    Milleron, B.
    Zalcman, G.
    ANNALS OF ONCOLOGY, 2012, 23 : 419 - 419
  • [38] Phase I trial of bi-weekly paclitaxel and gemcitabine as second-line therapy for patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy
    Tomonobu Koizumi
    Fumiaki Yoshiike
    Hitoshi Inou
    Orie Hatayama
    Mari Sasabayashi
    Kenji Tsushima
    Hiroshi Yamamoto
    Muneharu Hayasaka
    Keishi Kubo
    Medical Oncology, 2004, 21 : 133 - 138
  • [39] Phase I trial of Bi-weekly paclitaxel and gemcitabine as second-line therapy for patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy
    Koizumi, T
    Yoshiike, F
    Inou, H
    Hatayama, O
    Sasabayashi, M
    Tsushima, K
    Yamamoto, H
    Hayasaka, M
    Kubo, K
    MEDICAL ONCOLOGY, 2004, 21 (02) : 133 - 138
  • [40] Sequential carboplatin-gemcitabine (CG) and docetaxel (D) in the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC): A phase II trial.
    Murad, AM
    Guimaraes, RC
    Scalabrini-Neto, AO
    Papa, AM
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 708S - 708S
12345